depression

News

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

News

A $390m merger of two pioneers of psychedelic medicines has completed to create AtaiBeckley, with a pipeline of candidates for mental illnesses.

News

Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.

News

AbbVie could be heading for its second acquisition in the space of a month, as rumours emerge of a $1bn bid for psychiatric drug developer Gilgamesh.

News

The proposed merger between Beckley Psytech and atai can go ahead as a psychedelic for depression hits all its endpoints in a phase 2b trial.

News

A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.